Hitachi Medical Systems Europe Holding AG
2
Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI
plus
Actualités sur Medicale
LOG Pharma Packaging to Launch ActiveGuard® CONNECT(TM) at CPhI Worldwide 2019
Frankfurt, Germany (ots/PRNewswire) - Smart packaging solution boosts medication adherence by 23% LOG Pharma Packaging announced today that it will launch its innovative patent pending line of ActiveGuard® CONNECT(TM) smart packaging solutions at CPhI Worldwide 2019 in Frankfurt, Germany from 5-7 November. ActiveGuard® CONNECT(TM) was developed in cooperation with ...
plusClinicAll Enters Cooperation Partnership With The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group
New York (ots/PRNewswire) - ClinicAll International Corporation is excited to announce the strategic partnership with The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group. On 8th October 2019, Hisham Al Gurg, CEO of The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and the SEED Group, and ...
plus- 2
ClinicAll enters cooperation partnership with The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group
plus High Performance Swine Production With Reduced Use of Antibiotics: Second Workshop by EW Nutrition and OPP Group
Lleida, Spain (ots/PRNewswire) - From 4 to 7 November, in Lleida, Spain, OPP Group and EW Nutrition are hosting their second workshop on animal health and welfare with reduced antibiotic use The two-day event offers swine producers and other stakeholders essential, actionable information on developing profitable ...
plusRESTORE 1st Advanced Therapies Science Meeting
Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...
plus
Global Health Centre, The Graduate Institute of International and Development Studies
The Lancet and Financial Times partner for first joint Commission on Governing health futures 2030: Growing up in a digital world
plusEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
plusZentiva Acquires Central and Eastern European Business of Alvogen
Zentiva to further expand its geographical footprint and complement its portfolio in Generics and OTC Prague, Czech Republic and Sofia, Bulgaria (ots/PRNewswire) - Zentiva announces the signing of a definitive agreement to acquire the Central and Eastern European Business of Alvogen, for an undisclosed amount. Alvogen CEE markets over 200 generic and over-the-counter ...
plusUEG Week Exhibition Celebrates 50 Years of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer
Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...
plus- Oral ferric maltol may offer an alternative treatment option to IV iron even in patients who have failed or not tolerated current oral iron treatments[1]
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
plusFace Up To Rosacea: Galderma Launches Online Support to Empower and Equip Rosacea Sufferers to Discuss the True Burden of Their Disease With a Dermatologist
New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success Lausanne, Switzerland (ots/PRNewswire) - ...
plus
The International Osteoporosis Foundation (IOF)
2IOF: A fracture every 3 seconds worldwide - That's osteoporosis
plusThe procedure was performed by Jason M. Scopp, MD, an orthopedic surgeon at Peninsula Orthopaedic Clinic in Salisbury, Maryland
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C(TM) implant, as part of Investigational Device Exemption (IDE) clinical study by Dr. ...
plusEuropean Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban)
- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical ...
plusUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
plusA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
plusNovo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...
plus
Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More
Norderstedt, Germany (ots/PRNewswire) - Medical diagnostics company Sysmex Europe GmbH celebrates the 10th anniversary of the Sysmex Academy in October. Sysmex is the only company to have such a longstanding education system in place for both employees, distributors, and later on, end-customers. Every company wants to provide the best products and services possible to ...
plusFirst Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests
Madrid (ots/PRNewswire) - QUANTIC NANOTECH (https://qnanotech.com/), a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE (https://qnanotech.com/)" during the last CES 2019 Edition in Las Vegas, announced today the opening of free ...
plusAbstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
plusEASL European Association for the study of the Liver
2Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe
plusOrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent
Hong Kong (ots/PRNewswire) - OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] to combine the proprietary endothelial progenitor cell [EPC] capture technology with an ...
plusEthicon Launches New Powered Circular Stapler With Dual Technologies to Reduce Anastomotic Complications in Colorectal, Gastric, and Thoracic Surgery
Innovative technology helps address critical challenge of anastomotic leaks which can occur in up to 8.6% of colorectal surgeries1,11% in oesophagectomies2 and 4% in gastrectomies3 Vienna (ots/PRNewswire) - Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the launch of the ...
plus
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for ...
plusExperts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today
- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised3 - Specialists (82%) believe osteoporosis is a silent epidemic, yet only 24% believe their healthcare system is ...
plusHovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
plusCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
plusSOPHiA GENETICS Expands Executive Team With a Chief Marketing Officer and New Chief Information Officer
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly ...
plusTresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes
Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...
plus
Précédent15161718192021222324Suivant